Alphamab Oncology

Pathos AI has entered into a global licensing agreement with Alphamab Oncology for JSKN016, a first-in-class bispecific antibody-drug conjugate targeting TROP2 and HER3. The deal includes a non-refundable upfront payment of $125 million, milestone payments totaling up to $2.09 billion, and tiered royalties ranging from high single-digit to low double-digit percentages based on annual net sales in licensed territories. Pathos will advance JSKN016 globally excluding the Chinese Mainland, Hong Kong, Macau, and Taiwan, where Alphamab retains exclusive rights. The therapy is being developed for solid tumors and is under evaluation across four additional indications including lung, breast, gastric, and colorectal cancers. Pathos identified JSKN016 through its proprietary AI-driven Foundry platform, making it the fourth clinical-stage program in its pipeline.

WuXi AppTec released its 2026 half-year report, with first-half net profit attributable to the parent company surpassing 10 billion yuan for the first time to reach 11.08 billion yuan, up 29.43 percent year on year. The results triggered multiple limit-up moves in the CXO and pharmaceutical sectors across both A-shares and Hong Kong stocks on August 4. WuXi AppTec's A-shares hit the 10 percent daily limit up that day, while its Hong Kong shares closed 11.17 percent higher. The company's first-half revenue was 28.9 billion yuan, up 38.93 percent year on year, and it raised its full-year revenue guidance to a range of 58.5 billion to 60.5 billion yuan. Buoyed by WuXi AppTec's performance, A-share companies such as GemPharmatech, Porton Pharma Solutions, and Medicilon rose over 13 percent, while Hong Kong-listed GenScript Biotech gained over 11 percent, and Pharmaron, Asymchem, and Tigermed climbed more than 5 percent. Several CXO firms had previously issued positive profit alerts. Pharmaron expects first-half net profit to grow 34 to 45 percent year on year, Joinn Laboratories forecasts a staggering 884.9 to 1,377.4 percent surge in net profit attributable to the parent, and Medicilon anticipates swinging to a profit. The innovative drug segment also strengthened, with Biopuris and HitGen rising over 14 percent, while Luoxin Pharmaceuticals, Jimin Health, and ZBD Pharmaceutical hit the 10 percent daily limit up. Meanwhile, Alphamab announced it has granted overseas rights for its TROP2/HER3 bispecific antibody-drug conjugate SKN016 to Pathos AI, in a deal with a total potential value exceeding 2.2 billion US dollars.